Seer, which provides a proteograph product suite for biomedical research, filed on Thursday with the SEC to raise up to $150 million in an initial public offering. The company aims to commercialize ...

Fourth Quarter Revenue: $4 million, a decrease of 10% from $4.4 million in Q4 2023. Full Year Revenue: $14.2 million, a decrease of 15% from $16.7 million in 2023. Gross Margin (Q4 2024): 51%, up from ...

Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06 ...

Management reiterated 2025 revenue guidance of $17 million to $18 million, which represents 24% growth at the midpoint over 2024. Horn stated, "Our guidance range assumes our customers will continue ...

Good day, and welcome to the Seer, Inc. Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to ...

Seer, Inc. reported its financial results for the first quarter of 2025, highlighting a revenue of $4.2 million, a 37% increase from the same period last year, driven by higher product and service ...